Related references
Note: Only part of the references are listed.Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy
Tomasz Wysocki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis
Biljana Jekic et al.
PHARMACOGENOMICS (2019)
A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients
Cecile Luxembourger et al.
PHARMACOGENOMICS JOURNAL (2019)
Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology
Daniel Seoane-Mato et al.
REUMATOLOGIA CLINICA (2019)
Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis
M. Maldonado-Montoro et al.
PHARMACOGENOMICS JOURNAL (2018)
Pharmacogenomics of Methotrexate: Current Status and Future Outlook
Mengda Cao et al.
CURRENT DRUG METABOLISM (2018)
Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate-and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study
Graeme Jones et al.
JOURNAL OF RHEUMATOLOGY (2017)
IL6R haplotype rs4845625*T/rs4537545*C is a risk factor for simultaneously high CRP, LDL and ApoB levels
A. A. Arguinano et al.
GENES AND IMMUNITY (2017)
Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease
Thomas R. Webb et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis
S. Bek et al.
PHARMACOGENOMICS JOURNAL (2017)
A genetic risk score for CAD, psychological stress, and their interaction as predictors of CAD, fatal MI, non-fatal MI and cardiovascular death
Thomas Svensson et al.
PLOS ONE (2017)
Tocilizumab: A Review in Rheumatoid Arthritis
Lesley J. Scott
DRUGS (2017)
The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy
Maciej Tarnowski et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany
Christof Iking-Konert et al.
RHEUMATOLOGY (2016)
Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients
Patricia Moya et al.
PHARMACOGENOMICS (2016)
Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis
Mar Maldonado-Montoro et al.
PHARMACOLOGICAL RESEARCH (2016)
Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice
Javier Narvaez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice
Marina Backhaus et al.
CLINICAL RHEUMATOLOGY (2015)
The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis
Wenjuan Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study
Luz M. Canet et al.
PHARMACOGENETICS AND GENOMICS (2015)
FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors
Ariana Montes et al.
PHARMACOGENOMICS (2015)
Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis
Jacob Sode et al.
PLOS ONE (2015)
Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register
Helena Forsblad-d'Elia et al.
RHEUMATOLOGY (2015)
The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
Marita Cross et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
A Variant of IL6R Is Associated with the Recurrence of Atrial Fibrillation after Catheter Ablation in a Chinese Han Population
Gang Wu et al.
PLOS ONE (2014)
Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis
Christian Enevold et al.
PHARMACOGENETICS AND GENOMICS (2014)
Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?
Juliana Salazar et al.
PHARMACOGENOMICS (2014)
Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice
Yves-Marie Pers et al.
RHEUMATOLOGY (2014)
Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis
Ana Marquez et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Gene-Centric Analysis Identifies Variants Associated With Interleukin-6 Levels and Shared Pathways With Other Inflammation Markers
Tina Shah et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Large-scale association analysis identifies new risk loci for coronary artery disease
Panos Deloukas et al.
NATURE GENETICS (2013)
Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis
J. Wang et al.
PHARMACOGENOMICS JOURNAL (2013)
Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases
Ricardo C. Ferreira et al.
PLOS GENETICS (2013)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interleukin-6 Receptor Gene, Plasma C-Reactive Protein, and Diabetes Risk in Women
Lu Qi et al.
DIABETES (2009)
Triple therapy in early active rheumatoid arthritis
S. A. Saunders et al.
ARTHRITIS AND RHEUMATISM (2008)
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
S. M. M. Verstappen et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Comparison of treatment strategies in early rheumatoid arthritis - A randomized trial
Yvonne P. M. Goekoop-Ruiterman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels
David Reich et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states
D Aletaha et al.
ARTHRITIS AND RHEUMATISM (2005)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
C Grigor et al.
LANCET (2004)
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis
T Möttönen et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
